BavariaNephroBudesonide for IgA-Nephropathy, Phase 3
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01554-4/fulltext?rss=yes
Does the company have the guts to do a head-to-head-trial against regular budesonide?
Swapnil Hiremath 
MDThis is the methods section of interest - RASi βoptimizedβ ie the maximum tolerated dose had to be at least 50% of max (π) and BP < 150/100
Note biopsy timing doesnβt matter
Note exclusion for heart failure (Endothelin antagonist specific issue!)
This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period
2/
Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP
1/π§΅
Full text link via @Rheault_m
Big proteinuria reduction:
Phys.orgReferenced link: https://medicalxpress.com/news/2023-03-discovery-anti-mesangial-autoantibodies-redefines-pathogenesis.html
Discuss on https://discu.eu/q/https://medicalxpress.com/news/2023-03-discovery-anti-mesangial-autoantibodies-redefines-pathogenesis.html
Originally posted by Phys.org / @physorg_com: http://nitter.platypush.tech/medical_xpress/status/1638601461331382273#m
RT by @physorg_com: Discovery of anti-mesangial #autoantibodies redefines the pathogenesis of #IgAnephropathy @TUS_PR @ScienceAdvances https://medicalxpress.com/news/2023-03-discovery-anti-mesangial-autoantibodies-redefines-pathogenesis.html
Discovery of anti-mesangial autoantibodies redefines the pathogenesis of IgA nephropathy
IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney. In advanced stages of the disease, the buildup of IgA in the glomeruli disrupts kidney functioning and, in approximately 30% to 40% of cases, leads to kidney failure.
The rationale and design of the APPLAUSE IgAN trial of #iptacopan - a complement inhibitor - in #IgANephropathy - funded by its maker Novartis
Well timed for #NephMadness #IgANephropathy region! With a great #VisualAbstract from @edgarvlermamd
https://www.sciencedirect.com/science/article/pii/S2468024923000505
Tonight and tomorrow on #NephJC we discuss the NEFIGARD trial of #Nefecon (a targeted release #budesonide) in #IgANephropathy - supposedly with no systemic steroid exposure - but read the summary and decide for yourself http://www.nephjc.com/news/nefigard-trial
#nephrology #glomerulonephritis
#VisualAbstract from @Priti899
For a snapshot of all the trials so far, see this table made by Divya Bajpai
